The National Cancer Institute of the USA (NCI) has used the ligand-targeting properties of the RGD4C-AAVP to deliver tumor necrosis factor alpha (TNF-α) to the angiogenic vasculature of human melanoma xenografts in nude mice [56]. This evidence concerns the gene TNF and melanoma.